Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 16/20 | 0.40 |
| ▸ | CLK1 | P49759 | 3/20 | 0.38 |
| ▸ | CLK2 | P49760 | 3/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040661 | 0.83 | TTK (0.53) | TTKCLK1CLK2PIK3CBMAPK8 | |
| Ammonia Solution, Strong SCHEMBL3707460 | 0.74 | TTK (0.42) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL4766150 | 0.72 | TTK (0.54) | TTKPIK3CBMAPK8PTK2GAA | |
| Ammonia Solution, Strong SCHEMBL3695338 | 0.71 | LRRK2 (0.41) | TTK | |
| SCHEMBL4766022 | 0.71 | TTK (0.52) | TTKCLK1CLK2PIK3CBMAPK8 | |
| SCHEMBL4766587 | 0.71 | MAPT (0.45) | TTKGAA | |
| Ammonia Solution, Strong SCHEMBL3704523 | 0.70 | TTK (0.51) | TTKCAMKK2PIK3CBMAPK8PTK2 | |
| SCHEMBL3703793 | 0.70 | TTK (0.49) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL2948829 | 0.70 | TTK (0.55) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL3711102 | 0.69 | TTK (0.51) | TTKCLK1CLK2PIK3CBMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | TTK 4589/4885CLK1 3989/4885CLK2 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.